IMNN (Imunon) Cyclically Adjusted FCF per Share: $-346.94 (As of Mar. 2026)


IMNN Imunon Inc IMNN
26 GF Score
Price $1.98
! 3 Warning Signs
View Full Analysis

What is Imunon Cyclically Adjusted FCF per Share?

Imunon IMNN +3.66% 26 Cyclically Adjusted FCF per Share is $-346.94 as of Mar. 2026. GuruFocus rates IMNN with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Imunon's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.792. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-346.94 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 32.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 34.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Imunon was 38.10% per year. The lowest was -7.10% per year. And the median was 10.90% per year.

As of today (2026-07-07), Imunon's current stock price is $1.98. Imunon's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-346.94. Imunon's Cyclically Adjusted Price-to-FCF of today is .


Imunon  (NAS:IMNN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Imunon Cyclically Adjusted FCF per Share Related Terms


Imunon Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Imunon's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imunon Cyclically Adjusted FCF per Share Chart

Imunon Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,147.43 -1,311.37 -1,165.58 -763.31 -412.45

Imunon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -658.01 -567.82 -480.22 -412.45 -346.94

IMNN vs KAPA, HCWB, CURX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Imunon's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted Price-to-FCF falls into.


IMNN
26GF Score
Imunon Inc IMNN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imunon Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Imunon's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.792/330.2130*330.2130
=-0.792

Current CPI (Mar. 2026) = 330.2130.

Imunon Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -474.556 241.018 -650.178
201609 -472.800 241.428 -646.672
201612 -467.700 241.432 -639.686
201703 -350.111 243.801 -474.203
201706 -123.412 244.955 -166.366
201709 -124.561 246.819 -166.647
201712 -47.830 246.524 -64.067
201803 -52.056 249.554 -68.881
201806 -46.758 251.989 -61.273
201809 -46.923 252.439 -61.380
201812 65.533 251.233 86.135
201903 -57.969 254.202 -75.303
201906 -45.181 256.143 -58.246
201909 -41.027 256.759 -52.764
201912 -42.652 256.974 -54.808
202003 -37.750 258.115 -48.295
202006 -19.294 257.797 -24.714
202009 -22.793 260.280 -28.917
202012 -19.263 260.474 -24.420
202103 -36.848 264.877 -45.937
202106 -6.180 271.696 -7.511
202109 -8.699 274.310 -10.472
202112 -11.544 278.802 -13.673
202203 -18.174 287.504 -20.874
202206 -10.436 296.311 -11.630
202209 -8.634 296.808 -9.606
202212 -7.576 296.797 -8.429
202303 -6.362 301.836 -6.960
202306 -9.926 305.109 -10.743
202309 -6.555 307.789 -7.033
202312 -5.232 306.746 -5.632
202403 -8.164 312.332 -8.631
202406 -6.257 314.175 -6.576
202409 -3.146 315.301 -3.295
202412 -3.402 315.605 -3.559
202503 -2.388 319.799 -2.466
202506 -2.022 322.561 -2.070
202509 -1.508 324.800 -1.533
202512 -1.251 324.054 -1.275
202603 -0.792 330.213 -0.792

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-346.94 mean?
Imunon (IMNN) has a Cyclically Adjusted FCF per Share of $-346.94 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Imunon and its competitors.
Is Imunon's Cyclically Adjusted FCF per Share too high?
Imunon's current Cyclically Adjusted FCF per Share is $-346.94. Overall, Imunon has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Imunon's Cyclically Adjusted FCF per Share compare to KAPA and HCWB?
Imunon's Cyclically Adjusted FCF per Share of $-346.94 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Imunon and its competitors. Imunon's current Cyclically Adjusted FCF per Share is $-346.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imunon stock overvalued right now?
Imunon (IMNN) has a current Cyclically Adjusted FCF per Share of $-346.94. The current Cyclically Adjusted FCF per Share is $-346.94. Imunon's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Imunon (IMNN), the current Cyclically Adjusted FCF per Share is $-346.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imunon Business Description

Other Exchanges CBO0:Germany
Address 997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
26GF Score

Get the complete analysis for IMNN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.98
Price